1-Benzylimidazole |
| Catalog No.GC17678 |
selective inhibitor of thromboxane synthase
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4238-71-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Benzylimidazole is a selective inhibitor of thromboxane synthase and a stimulator of UDP-glucuronosyltransferase [1,2].
Thromboxane synthase is a cytochrome P450 enzyme. The cytochrome P450 proteins have been involved in catalyzing many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids. The enzyme plays an important role in several pathophysiological processes including hemostasis, cardiovascular disease, and stroke. The gene expresses two transcript variants [3].
1-Benzylimidazole selectively inhibited the activity of thromboxane synthase. 1-Benzylimidazole reduced TXB2 levels and increased blood flow in ischemia-reperfusion injury of rat brain [1]. In male Wistar rats, gastrically administration of 1-benzylimidazole (25, 75 and 100 mg/kg/day) caused a dose-dependent hepatomegaly. 1-Benzylimidazole decreased the plasma level in triglycerides by 60–70%. 1-benzylimidazole stimulated three distinct forms of UDP-glucuronosyltransferase. 1-benzylimidazole significantly increased the activities towards 4-methylumbelliierone, 1-naphthol, morphine or a monoterpenoid alcohol, nopol [2]. Benzylimidazole increased hepatocellular CYP1A catalytic activity and CYP1A mRNA in a concentration-dependent way [4].
References:
[1] Pettigrew L C, Grotta J C, Rhoades H M, et al. Effect of thromboxane synthase inhibition on eicosanoid levels and blood flow in ischemic rat brain[J]. Stroke, 1989, 20(5): 627-632
[2]. Magdalou J, Totis M, Boiteux-Antoine A F, et al. Effect of 1-benzylimidazole on cytochromes P-450 induction and on the activities of epoxide hydrolases and UDP-glucuronosyltransferases in rat liver[J]. Biochemical pharmacology, 1988, 37(17): 3297-3304.
Shen R F, Tai H H. Thromboxanes: synthase and receptors[J]. Journal of biomedical science, 1998, 5(3): 153-172.
[3] Shen R F, Tai H H. Thromboxanes: synthase and receptors[J]. Journal of biomedical science, 1998, 5(3): 153-172.
[4] Navas J M, Chana A, Herradón B, et al. Induction of CYP1A by the N‐imidazole derivative, 1‐benzylimidazole[J]. Environmental toxicology and chemistry, 2003, 22(4): 830-836.
| Cas No. | 4238-71-5 | SDF | |
| Chemical Name | 1-(phenylmethyl)-1H-imidazole | ||
| Canonical SMILES | c1ccc(cc1)Cn1cncc1 | ||
| Formula | C10H10N2 | M.Wt | 158.2 |
| Solubility | DMF: >530 µ g/ml,DMSO: >560 µ g/ml,Ethanol: >500 µ g/ml,PBS pH 7.2: >6.5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.3211 mL | 31.6056 mL | 63.2111 mL |
| 5 mM | 1.2642 mL | 6.3211 mL | 12.6422 mL |
| 10 mM | 0.6321 mL | 3.1606 mL | 6.3211 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *